UNC Lead Academic Participating Site

北卡罗来纳大学莱恩伯格综合癌症中心(UNC LCCC)寻求继续担任首席学者 国家临床试验网络(NCTN)的参与网站。北卡罗来纳大学LCCC是唯一由NCI指定的公共NCI 位于北卡罗来纳州的综合性癌症中心，致力于改善全美癌症患者的预后 不断发展的状态。在2015年的最近一次审查中，美国国家癌症研究所以2.33亿美元的癌症收入被美国国家癌症委员会评为“例外”-- 相关的校外资金，北卡罗来纳大学LCCC有一个出色的临床/转译研究计划，包括 集中式临床试验办公室，辅以高度参与的翻译部分。这位首席学者 参与站点(LAPS)应用反映了我们的临床研究计划目标，即通过以下方式改善癌症治疗 进行改变实践的临床试验并促进研究，以告知下一代临床 审判。北卡罗来纳大学LCCC在临床研究方面的全国地位体现在它是少数几个获得 在上一个资助周期中获得了三项具有竞争力的NCI临床研究奖(NCTN LAPS奖、三中心UM1奖 参与实验治疗学临床试验网络(ETCTN)和NCTN集成的赠款 技术科学中心(ITSC)奖)。作为国家临床试验网络(NCTN)的领先学术机构 参与现场，北卡罗来纳大学LCCC计划实现以下目标：(1)提供科学领导和 智力投入，以创造深思熟虑的、可行的试验，以改善癌症患者的健康； 通过我们不断增长的临床业务，以强劲的收益支持NCTN试验；以及(3)提供机会 在NCTN试验中嵌入并提供信息的优秀翻译科学。

UNC Lineberger Comprehensive Cancer Center (UNC LCCC) seeks to continue to serve as a Lead Academic Participating Site for the National Clinical Trials Network (NCTN). UNC LCCC is the only public NCI-designated comprehensive cancer center in North Carolina, dedicated to improving outcomes of cancer patients across this growing state. Ranked “Exceptional” by the NCI at the most recent review in 2015 and with $233M in cancer- related extramural funding, UNC LCCC has an outstanding Clinical/Translational Research Program including a centralized clinical trials office complemented by a highly engaged translational component. This Lead Academic Participating Site (LAPS) application mirrors our clinical research program goal to improve cancer treatment by conducting practice-changing clinical trials and fostering research that will inform the next generation of clinical trials. UNC LCCC’s national stature in clinical research is illustrated by being one of a few centers to receive all three competitive NCI clinical research awards in the last funding cycle (an NCTN LAPS award, a tri-center UM1 grant for participation in the Experimental Therapeutics Clinical Trials Network (ETCTN) and an NCTN Integrated Technology Science Center (ITSC) award). As a National Clinical Trials Network (NCTN) Lead Academic Participating Site, UNC LCCC plans to accomplish the following aims: (1) To provide scientific leadership and intellectual input into the creation of thoughtful, feasible trials to improve the health of cancer patients; (2) To support NCTN trials with robust accrual through our growing clinical enterprise; and (3) To provide opportunities for excellent translational science embedded into and informing NCTN trials.